Lorenzen S, Thuss-Patience P, Pauligk C, Gokkurt E, et al. FOLFIRI plus ramucirumab versus paclitaxel plus ramucirumab as second-line therapy for patients with advanced or metastatic gastroesophageal adenocarcinoma with or without prior docetaxel - results from the phase II RAMIRIS Study of the German Gastric Eur J Cancer 2022;165:48-57.
PMID: 35202974